- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced achievement of its device performance targets for the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.
The company announced during its recent quarterly conference call that it had preliminary results from animal testing indicating achievement of both its device function targets and its performance target of greater than or equal to 15% average bioavailability with the autonomous version of its next-generation device. As planned, the company subsequently conducted repeat studies and has now confirmed the achievement of its development targets for the BioJet platform.
https://finance.yahoo.com/news/biora-therapeutics-progresses-biojet-systemic-120000364.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.